ライフサイエンスコーパス: lansoprazole

1 (pantoprazole, omeprazole, esomeprazole, or lansoprazole).

2 esomeprazole but not with dexlansoprazole or lansoprazole.

3 All patients received lansoprazole.

4 pH (confirmed by 24-hour pH monitoring) with lansoprazole.

5 negative breath test result while receiving lansoprazole.

6 nsoprazole and 67% of recipients of 30 mg of lansoprazole.

7 azole and 90% of patients receiving 30 mg of lansoprazole.

8 r esomeprazole, 1.49 (95% CI, 1.25-1.78) for lansoprazole, 1.43 (95% CI, 1.35-1.51) for omeprazole, a

9 g bolus followed by 9-mg/h infusion) or oral lansoprazole (120-mg bolus followed by 30 mg every 3 hou

10 ontrol 68.3+/-37.8; ranitidine 38.4 +/-94.2; lansoprazole 14.6+/-84.4; and omeprazole 15.1+/-48.9.

11 Lansoprazole, 15 mg or 30 mg, or placebo once daily for

12 ily vonoprazan, 10 mg, vonoprazan, 20 mg, or lansoprazole, 15 mg, for 24 weeks.

13 ren were randomly assigned to receive either lansoprazole, 15 mg/d if weighing less than 30 kg or 30

14 measure, including RSI scores at 12 months: lansoprazole 16.0 (13.6 to 18.4) and placebo 13.6 (11.7

15 e observed in both groups-score at 16 weeks: lansoprazole 17.4 (15.5 to19.4) and placebo 15.6 (13.8 t

16 similar between treatment arms at baseline: lansoprazole 22.0 (95% confidence interval 20.4 to 23.6)

17 groups of media: a) control; b) control plus lansoprazole (25 microg/mL); c) control plus omeprazole

18 ithromycin 500 mg, metronidazole 400 mg, and lansoprazole 30 mg (active eradication), or oral placebo

19 ith or without a PPI (dexlansoprazole 60 mg, lansoprazole 30 mg, esomeprazole 40 mg, or, as a positiv

20 ple therapy twice a day (vonoprazan 20 mg or lansoprazole 30 mg; amoxicillin 1 g; clarithromycin 500

21 Lansoprazole, 30 mg twice daily, produced symptom resolu

22 ndomized to once-daily vonoprazan, 20 mg, or lansoprazole, 30 mg, for up to 8 weeks.

23 were reported, 455 for esomeprazole, 433 for lansoprazole, 421 for pantoprazole, and 405 for rabepraz

24 -pyridyl)methylsulfinyl]-1H-ben zimida zole (lansoprazole), 5-difluoromethoxy-2-[3, 4-methoxy-2-pyrid

25 >/=18 years, 50 mg for those <18 years) and lansoprazole (60 mg for participants >/=18 years, 30 mg

26 relatively acid stable analogue, N(1)-methyl lansoprazole, (6b), allowed direct determination of both

27 They were randomly assigned to intravenous lansoprazole (90-mg bolus followed by 9-mg/h infusion) o

28 ceftriaxone (a cephalosporin antibiotic) and lansoprazole (a proton-pump inhibitor) will prolong the

29 Recent studies indicate that lansoprazole-a known gastric proton pump inhibitor and i

30 whom acid secretion status was monitored on lansoprazole, all were free of significant gastrointesti

31 a dynamic balancing procedure to: 14 days of lansoprazole, amoxicillin, and clarithromycin (standard

32 omization to 1 of 3 treatment groups: 14-day lansoprazole, amoxicillin, and clarithromycin (triple th

33 in, and metronidazole (sequential); or 5-day lansoprazole, amoxicillin, clarithromycin, and metronida

34 clarithromycin (standard therapy); 5 days of lansoprazole, amoxicillin, clarithromycin, and metronida

35 everity of symptoms (mild or severe): 172 to lansoprazole and 174 to placebo.

36 e 50.0% (10.0%-72.0%) for participants given lansoprazole and 5.0% (0.0%-40.0%) for participants give

37 compared with 72% of recipients of 15 mg of lansoprazole and 67% of recipients of 30 mg of lansopraz

38 ared with 79% of patients receiving 15 mg of lansoprazole and 90% of patients receiving 30 mg of lans

39 nidazole (concomitant therapy); or 5 days of lansoprazole and amoxicillin followed by 5 days of lanso

40 , and clarithromycin (triple therapy); 5-day lansoprazole and amoxicillin followed by 5-day lansopraz

41 study suggest that combination therapy with lansoprazole and ceftriaxone should be avoided.

42 ive control, we evaluated the combination of lansoprazole and cefuroxime (another cephalosporin), whi

43 ed DNA synthesis in PBMCs when compared with lansoprazole and omeprazole.

44 .05), and no significant difference between lansoprazole and omeprazole.

45 RSI scores were similar between the lansoprazole and placebo groups after 16 weeks of treatm

46 proton pump inhibitor such as omeprazole or lansoprazole, and eradicating H pylori with treatment su

47 s of many TB drugs, further investigation of lansoprazole as a potential antituberculosis agent is wa

48 Lansoprazole bound to the cysteines in these two domains

49 e is no evidence that, in clinical practice, lansoprazole can treat or prevent incident tuberculosis

50 nsoprazole and amoxicillin followed by 5-day lansoprazole, clarithromycin, and metronidazole (sequent

51 razole and amoxicillin followed by 5 days of lansoprazole, clarithromycin, and metronidazole (sequent

52 s suggested this interaction was specific to lansoprazole combined with ceftriaxone but not with othe

53 improved significantly among patients given lansoprazole compared with placebo.

54 ing inhaled corticosteroids, the addition of lansoprazole, compared with placebo, improved neither sy

55 ference, 15.7%; 95% CI, 2.5%-28.4%; 10 mg vs lansoprazole: difference, 13.3%; 95% CI, 0.02%-26.1%).

56 e of healing Grade C/D esophagitis (20 mg vs lansoprazole: difference, 15.7%; 95% CI, 2.5%-28.4%; 10

57 fference, 8.7%; 95% CI, 1.8%-15.5%; 10 mg vs lansoprazole: difference, 7.2%; 95% CI, 0.2%-14.1%) and

58 analysis of maintenance of healing (20 mg vs lansoprazole: difference, 8.7%; 95% CI, 1.8%-15.5%; 10 m

59 Complete symptom eradication with lansoprazole does not guarantee normalization of intraes

60 The 15-mg and 30-mg lansoprazole doses did not differ significantly for use

61 The 15-mg and 30-mg lansoprazole doses did not differ significantly in maint

62 Lansoprazole during ceftriaxone treatment vs other PPIs

63 Lansoprazole effectively maintains healing of erosive es

64 Prescription of omeprazole, pantoprazole, lansoprazole, esomeprazole, or rabeprazole.

65 Lansoprazole for persistent throat symptoms in secondary

66 Patients enrolled in a long-term trial of lansoprazole for Zollinger-Ellison syndrome and other ac

67 The study included 3747 patients in the lansoprazole group and 27 405 patients in the other PPI

68 occurred in 746 patients (19.9%) within the lansoprazole group and 2762 patients (10.1%) in the othe

69 on of hospital stay was 1.8 days in the oral lansoprazole group and 3.9 days in the intravenous esome

70 t occurred in 126 patients (3.4%) within the lansoprazole group and 319 patients (1.2%) within the ot

71 scores, the adjusted risk difference for the lansoprazole group minus other PPI group was 1.7% (95% C

72 red with more than 90% of patients in either lansoprazole group.

73 tive metabolite (omeprazole > esomeprazole > lansoprazole > dexlansoprazole) and showed a correspondi

74 patients with a hypersensitivity reaction to lansoprazole had a positive OPT or skin test result with

75 nd that patients taking both ceftriaxone and lansoprazole had significantly longer QTc intervals (up

76 The combination of ceftriaxone and lansoprazole has been shown to prolong the corrected QT

77 azan was noninferior and superior to the PPI lansoprazole in healing and maintenance of healing of er

78 ansoprazole metabolite, was more active than lansoprazole in inhibiting FASN function and regulation

79 tenance phase, vonoprazan was noninferior to lansoprazole in the primary analysis and superior on the

80 healing phase, vonoprazan was noninferior to lansoprazole in the primary analysis and superior on the

81 , 5HLS inhibits the enoyl reductase, whereas lansoprazole inhibits the thioesterase of FASN.

82 We identified 527,364 lansoprazole initiators and 923,500 omeprazole or pantop

83 Combination therapy of ceftriaxone and lansoprazole is associated with increased risk of acquir

84 roton pump inhibitors, such as omeprazole or lansoprazole, is the primary treatment.

85 clinical trial to investigate the effects of lansoprazole (LANZO) administration, a proton pump inhib

86 hydroxy lansoprazole sulfide (5HLS), the end lansoprazole metabolite, was more active than lansoprazo

87 The mean difference in change (lansoprazole minus placebo) in the ACQ score was 0.2 uni

88 The suspected PPIs were lansoprazole (n = 52), esomeprazole (n = 11), pantoprazo

89 7.6% (33 potentially interacting drugs) for lansoprazole of the total identified drugs at risk of in

90 ffects of Multiple Doses of Dexiansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmaco

91 HODS AND We studied a cohort of new users of lansoprazole, omeprazole, or pantoprazole from the Unite

92 edical inpatients receiving ceftriaxone with lansoprazole or another PPI in 13 hospitals in Ontario,

93 copic therapy were randomly assigned as oral lansoprazole or intravenous esomeprazole group.

94 8 weeks, along with a proton-pump inhibitor (lansoprazole or omeprazole) and bismuth subsalicylate.

95 Similar data were found for lansoprazole or rabeprazole.

96 m SPCs for 5 PPIs (omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole) and 5 ICs (

97 e minimized by the use of dexlansoprazole or lansoprazole rather than esomeprazole or omeprazole.

98 months, 35% of placebo recipients and 2% of lansoprazole recipients had three or more recurrences.

99 ment with the furazolidone, tetracycline and lansoprazole regimen, twice a day for 7 days.

100 se events was similar between vonoprazan and lansoprazole regimens (P > .05).

101 Children treated with lansoprazole reported more respiratory infections (relat

102 Lansoprazole showed no benefits over placebo for any sec

103 rly, esomeprazole but not dexlansoprazole or lansoprazole significantly reduced the effect of clopido

104 ted this hypothesis and found that 5-hydroxy lansoprazole sulfide (5HLS), the end lansoprazole metabo

105 inhibitor and its intracellular metabolite, lansoprazole sulfide (LPZS)-are potential antituberculos

106 assay to show that, as proposed previously, lansoprazole sulfide is an inhibitor of Complex III(2)IV

107 st results were positive after completion of lansoprazole therapy were 91% (95% CI, 83% to 96%) at 3

108 s have found the proton pump inhibitor (PPI) lansoprazole to be highly active against Mycobacterium t

109 The other three drugs namely lansoprazole, tolvaptan and roflumilast, were less poten

110 zan triple and dual therapy were superior to lansoprazole triple therapy (80.8% and 77.2%, respective

111 triple therapy 65.8%, dual therapy 69.6%, vs lansoprazole triple therapy 31.9% (both superior; differ

112 triple therapy 84.7%, dual therapy 78.5%, vs lansoprazole triple therapy 78.8% (both noninferior; dif

113 dom blinded allocation (1:1) to either 30 mg lansoprazole twice daily or matched placebo twice daily

114 drainage to groups that were given 30 mg of lansoprazole twice daily or placebo.

115 Lansoprazole users had a lower rate of TB disease (n = 8

116 ctice Research Datalink to determine whether lansoprazole users have a lower incidence of TB disease

117 a positive pH study, no treatment effect for lansoprazole vs placebo was observed for any asthma outc

118 There was a significant difference between lansoprazole vs. ranitidine (p< .01), and omeprazole vs.

119 ommonly prescribed and cheaply available PPI lansoprazole was associated with reduced incidence of TB

120 Lansoprazole was significantly superior to placebo in ma

121 After 8 and 16 weeks, participants given lansoprazole were 3.12-fold (1.28-7.59) and 3.50-fold (1

122 y the coadministration of dexlansoprazole or lansoprazole with clopidogrel than by the coadministrati

123 olled, parallel clinical trial that compared lansoprazole with placebo in children with poor asthma c

124 transmission, nor could we determine whether lansoprazole would have a beneficial effect if given to

125 We postulated that sitagliptin and lansoprazole would preserve beta-cell function in patien